Sé zary syndrome (SS) is an aggressive variant of cutaneous T-cell lymphoma. During disease progression, immunodeficiency develops; however, the underlying molecular and cellular mechanisms are not fully understood. Here, we study the regulatory T cell (Treg) function and the expression of FOXP3 in SS. We demonstrate that malignant T cells in 8 of 15 patients stain positive with an anti-FOXP3 antibody. Western blotting analysis shows expression of two low molecular splice forms of FOXP3, but not of wild-type (wt) FOXP3. The malignant T cells produce interleukin-10 and TGF-b and suppress the growth of non-malignant T cells. The Treg phenotype and the production of suppressive cytokines are driven by aberrant activation of Jak3 independent of the FOXP3 splice forms. In contrast to wt FOXP3, the low molecular splice forms of FOXP3 have no inhibitory effect on nuclear factor-jB (NF-jB) activity in reporter assays which is in keeping with a constitutive NF-jB activity in the malignant T cells. In conclusion, we show that the malignant T cells express low molecular splice forms of FOXP3 and function as Tregs. Furthermore, we provide evidence that FOXP3 splice forms are functionally different from wt FOXP3 and not involved in the execution of the suppressive function. Thus, this is the first description of FOXP3 splice forms in human disease.
Introduction
Mycosis fungoides (MF) and the leukemic variant Sézary syndrome (SS) are the two major clinical forms of cutaneous T-cell lymphoma (CTCL). The etiology remains poorly understood, but occupational exposures, infectious agents and genetic mutations have been proposed as etiological factors. In the initial phase, which can last a number of years, MF presents as flat erythematous skin patches, resembling chronic inflammation seen in chronic skin infections, psoriasis and eczema. In the later stages, MF lesions gradually form plaques and overt tumors, and eventually involve lymph nodes and internal organs. [1] [2] [3] [4] [5] SS is a particular aggressive variant of CTCL with a mean survival of 3 years from the time of diagnosis. The disease is characterized by the presence of circulating lymphocytes with atypical cerebriform nuclei (Sézary cells) in the skin, lymph nodes and peripheral blood. 1 The early skin lesions contain a mixture of cells, including malignant T cells that phenotypically resemble normal activated CD4
þ T lymphocytes as well as non-malignant tumor-infiltrating T cells, dendritic cells, macrophages and other inflammatory cells. [1] [2] [3] [4] [5] During the course of the disease, a shift in the composition of infiltrating T cells takes place and the interactions between malignant and non-malignant cells change. 6 In the early stages of the disease, the infiltrate consists primarily of non-malignant T helper 1 (T H 1) cells and cytotoxic CD8 þ T cells, which appear to control the malignant T cells through inhibitory cytokines, such as interferon (IFN)-a and IFN-g, and cytotoxicity directed against malignant T cells expressing tumorassociated antigens. [7] [8] [9] In later stages of the disease, the malignant T cells show aberrant hyperactivation of Janus kinase-3 (Jak3) 10 and signal tranducers and activators of transcription (STAT) 11, 12 proteins, which in turn trigger survival signals and the expression of suppressor of cytokine signalling-3 (SOCS3). 13 SOCS3 protects the malignant T cells from inhibition by IFNs 13 and is a marker of a poor prognosis. 14 During disease progression, the normal T-cell compartment is depleted and the immune system becomes increasingly compromised, leading to a state of immunodeficiency. Indeed, patients with advanced lesions frequently die of opportunistic infections rather than complications from the tumor burden. 15 Using an in vitro model, Berger et al. 16 recently provided evidence that CTCL involves a malignant proliferation of regulatory T cells (Tregs) with the capacity to inhibit normal T-cell function and poiesis. To test this hypothesis, several studies have addressed whether malignant T cells from SS or MF have a regulatory phenotype in vivo. [17] [18] [19] The most specific and widely used marker for Tregs is FOXP3, a member of the forkhead family of DNA-binding proteins. 20 However, in a previous study, Klemke et al. 17 found a decrease in CD4 þ FOXP3 þ cells within the dermal lymphomononuclear infiltrate of SS patients when compared with control samples, indicating that the malignant T cells do not express FOXP3. Similarly, malignant T cells in MF very rarely express FOXP3 as judged from immunohistochemical analysis of tissue sections from MF patients. 17, 19 Recently, two low molecular splice forms of FOXP3, designated FOXP3D2 and FOXP3D2D7, have been identified. 21, 22 As shown in Figure 1 , both splice forms lack exon 2, which is a central part of the N-terminal proline-rich sequence (repressor region) that has been shown to be important for FOXP3-mediated transcriptional repression. [23] [24] [25] Moreover, the FOXP3D2D7 splice form lacks exon 7, which constitute a major part of a leucine zipper domain that is essential for FOXP3 homodimerization. 23 However, little is known about the biological functions of the low molecular splice forms of FOXP3 and no studies have addressed their role in human disease. Here, we have investigated the expression of FOXP3 in SS, and provide the first evidence that the malignant T cells selectively express the two low molecular splice forms of FOXP3 and that the splice forms differ functionally from wt FOXP3 in terms of nuclear factor-kB (NF-kB) regulation. Furthermore, we have investigated the suppressive capacity of the malignant T cells and show that they are functional Tregs in vitro. As malignant expression of FOXP3 splice forms and Treg function is driven by Jak3, our study sheds new light on the function of the Jak3/STAT pathway in malignant transformation and immunodeficiency in cancer.
Materials and methods

Antibodies and reagents
Antibodies (Abs) against Erk1/2 (K-23) and Jak3 (C-21) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Abs against Stat3 (no. 9132), phospho-Stat5 (no. 9351), NF-kB (no. 3034) and IkB-a (no. 9242) were obtained from Cell Signaling Technology (Beverly, MA, USA); and the IL-10RA monoclonal Ab (mAb) (MAB274) from R&D Systems (Minneapolis, MN, USA). The phospho-Stat3 (Y705) mAb was from NanoTools (Denzlingen, Germany), whereas the Stat5 mAb (610192) was from Becton Dickinson (BD) (Franklin Lakes, NJ, USA). The FOXP3 mAbs 236A/E7 (no. 14-4777) and 150D/E4 (no. 14-4774) were from eBioscience (San Diego, CA, USA). The FITC-conjugated CD25 (F0801) mAb was purchased from Dako (Glostrup, Denmark), whereas the APC-conjugated CTLA-4 mAb (555855) together with respective fluorochrome-conjugated isoform control Abs was obtained from BD. FOXP3, Stat3, Stat5a, Stat5b, Jak3 and non-targeting ON-TARGETplus SMARTpool siRNA were purchased from Dharmacon (Chicago, IL, USA). The Jak3 inhibitor (Jak3I) (WHI-P154) (no. 420104), the Lck inhibitor (LckI) (no. 428205), the NF-kB activation inhibitor (NFkBI) (no. 481406) and PD98059 (no. 513000) were purchased from Calbiochem (San Diego, CA, USA). Finally, tyrphostin Ag1478 and PP1 were from Alexis (Laufelfingen, Switzerland).
Patients
After review of histological samples and clinical records, a total of 15 patients were found diagnosed with SS. The patients were 12 males and 3 females with a mean age of 69 years (range . Survival data could be retrieved for five of the cases and the median survival was 40 months. Biopsies from 11 patients (diagnosed with SS during the period 1979-2004) were drawn from the archives at the Department of Pathology at Rigshospitalet and at the University of Copenhagen, Bispebjerg Hospital. Primary tumor cells were acquired from peripheral blood of six patients. From two patients, both skin biopsies and primary tumor cells from peripheral blood could be obtained. Peripheral blood CD3 counts were between 3729 and 33 800 (mean value of 13 600), CD4/CD8 ratios between 18:1 and 386:1 (mean value of 270:1) and percentages of CD4 þ , CD26
À cells between 78 and 96% (mean value of 88%).
Cell lines and cell culture
The malignant T-cell lines SeAx and Sez-4 were established from peripheral blood of patients diagnosed with SS as described earlier. 26, 27 The malignant T-cell line, MyLa2000 (MF2000), and the non-malignant T-cell lines, MySi and MF1850, were obtained from patients with MF. [28] [29] [30] The Jurkat T-cell line, J-Tag, and the B-cell line, Ramos 2G6.AC10, have previously been described. 31, 32 MF2000, Jurkat and Ramos were grown in conditional media (RPMI 1640, 2 mM L-glutamine, 100 mg/ml penicillin/streptomycin all from Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Roskilde, Denmark). SeAx and Sez-4 were grown in conditional media supplemented with 10% pooled human serum (Blood Bank, State University Hospital, Copenhagen, Denmark) and 10 3 U/ml IL-2 (Proleukin) (Chiron, Emeryville, CA, USA). Finally, MySi and MF1850 were grown in the same media as SeAx except that 25 ng/ml IL-4 (Leinco, St Louis, MO, USA) was added.
Immunohistochemistry
Following microwave heat-induced epitope retrieval, sections were incubated for 60 min at room temperature with a 1:50 dilution of FOXP3 Ab (236A/E7) and then stained using the DAKO Real EnVision Detection System, Peroxidase/DAB, Rabbit/Mouse (K5007) by the Techmate 500 Immunostainer. Scoring of FOXP3 þ malignant T cells was performed by two of the authors (LMG and ER). FOXP3 labeling of the malignant T cells was scored as negative (no visible staining or positive staining in o10%), moderately positive (positive staining in 10-50% of the malignant T cells) and positive in a majority (450%) of the malignant T cells.
Protein extraction and western blotting
Protein extraction and western blotting (WB) were performed as described earlier. 10 To ensure equal loading, the total protein concentration of each sample was determined by Bio-Rad Protein Assay (no. 500-0001; Bio-Rad, Hercules, CA, USA). 
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Preparation of cytoplasmic and nuclear protein extractions was made using the NucBuster protein extraction kit from Novagen, following the manufacturer's protocol (Novagen, Merck KGaA, Darmstadt, Germany).
Plasmid constructs
The NF-kB-Luc reporter construct were a generous gift from Dr Mohamed Oukka, and has been described earlier.
24 FOXP3 splice variants ÀD2 and ÀD2D7 were cloned from SeAx cDNA using PCR with primers containing restriction sites for HindIII in the forward primer: 5 0 -CCCAAGCTTTGGACAAGGACCCGA TG, and XhoI in the reverse primer: 5 0 -CCGCTCGAGGGGGC CAGGTGTAGGGT. The products were ligated into pcDNA3.1 expression vector (Invitrogen, Carlsbad, CA, USA). FOXP3 wt was cloned from an FOXP3-positive non-malignant cell line as described above. All tree inserts were re-cloned into the HA-tagged expression vector pET/HA (a generous gift from Dr Thomas Mustelin 33 ) using PCR with primers containing restriction sites for EcoRI in the forward primer: 5 0 -GGAATTCTTG GACAAGGACCCGATG, and SpeI in the reverse primer: 5 0 -GA CTAGTCTCAGGGGCCAGGTGTAGGGT. All PCR reactions were conducted using the Phusion high-fidelity DNA polymerase in accordance with the manufacturer's instruction (Finnzymes, Espoo, Finland). All expression constructs were sequenced bidirectional, and no errors were found.
Transient transfections of siRNA
Transient transfections were essentially performed as described earlier 34 using 0.5 nmol of the respective ON-TARGETplus SMARTpool siRNAs and 2 Â 10 6 cells.
Enzyme-linked immunosorbent assay
Cells (1 Â 10 6 cells per sample) were washed extensively and resuspended in 1 ml fresh cytokine-free media in a 12-well plate. Subsequently, the cells were incubated for 8 or 24 h, with the given concentrations of inhibitors. Finally, the supernatants were harvested, and the concentrations of IL-10 and TGF-b1 was measured by ELISA using IL-10 (DY217B) or TGF-b1 (DY240) Human DuoSet ELISA Development Kits purchased from R&D Systems. For TGF-b1 ELISA, the cells were grown in 1% human serum to minimize the background level of TGF-b1. Moreover, supernatants subjected to TGF-b1 ELISA were activated prior ELISA analysis in accordance with the manufacturer's instructions.
Mixed lymphocyte culture and proliferation assays
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats from healthy donors provided by the University Hospital of Copenhagen using Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) density gradient centrifugation. Then, the PBMCs were washed and resuspended in conditional media containing 10% human serum. Stimulator cells were irradiated for 10 min at 3000 rad and mixed 1:1 with responder cells in the bottom chamber of a 12-well plate with transwell inserts (pore size 0.4 mM) (Greiner Bio-One, Frickenhausen, Germany) in the presence or absence of SeAx cells in the upper chamber and anti-IL-10RA (500 mg/ml) or anti-TGF-b (0.1 mg/ml) as given. The cells were cultured for 5 days with the addition of 7 mCi [ 3 H]thymidine to each well 20 h prior harvest. Finally, the samples from the bottom chamber were transferred to 96-well round-bottomed plates, harvested onto glass fiber filters and the [ 3 H]thymidine incorporation was measured in a TopCount scintillation counter (PerkinElmer, Waltham, MA, USA). The proliferation was expressed as mean counts per minute (CPM) of given numbers of replicate cultures. Similarly, non-malignant T cells from a CTCL patient (MF1850) were cultured in conditional media with 10% human serum and 1000 U/ml IL-2 in the bottom chamber with or without SeAx in the upper chamber. The SeAx cells were either transfected or not transfected with non-targeting or FOXP3 siRNA 24 h before co-culture. After 3 days of culture, 7 mCi of [ 3 H]thymidine was added to each well and incorporation determined as described. 35 
RNA purification and RT-PCR
Total cellular mRNA was isolated using the RNeasy RNA purification kit from Qiagen with the addition of on-column DNase digestion to avoid DNA contamination as described by the manufacturer (Qiagen, Hilden, Germany). Purified RNA was reverse transcribed using murine Moloney leukemia virus reverse transcriptase (M-MLV, Invitrogen). The resulting cDNA was amplified by PCR using recombinant Taq 
Flow cytometry
For surface staining, cells were harvested, washed in ice-cold FACS buffer (phosphate-buffered saline (137 mM NaCl, 10 mM phosphate, 2.7 mM KCL, pH 7.4), 5% FBS and 0.1% sodium azide) and stained with 5 ml FITC-conjugated anti-CD25 or isotype control Abs for 30 min at 4 1C in the dark. For intracellular staining, cells were harvested, washed in phosphate-buffered saline and fixed and permeabilized using BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (554714) according to the manufacturer's protocol. Then, they were stained with 5 ml APC-conjugated anti-CTLA-4 or isotype control Abs for 30 min at 4 1C in the dark. After final washing, the cells were resuspended in FACS buffer and analyzed on a FACSCalibur using CellQuest software (BD).
Luciferase assay
Jurkat J-TAg cells were transiently co-transfected with 1.0 mg NF-kB-Luc reporter construct, 3.0 mg of a pcDNA3.1 expression vector either empty or encoding FOXP3-wt, ÀD2 or ÀD2D7, respectively, and 0.5 mg Renilla luciferase control vector (pRL-CMV; Promega, Madison, WI, USA) with the DMRIE-C transfection reagent, according to the manufacturer's protocol (no. 10459-014, Invitrogen). At 24 h after transfection, cells were left unstimulated or stimulated with 10 ng/ml flagellin (Alexis) for an additional 24 h. The cells were harvested, and the luciferase activities were determined by using the DualLuciferase Reporter Assay system (Promega) according to the manufacturer's instruction. The co-expressed Renilla luciferase activity was used for normalization of transfection efficiency. 
Results
Malignant T cells express FOXP3 splice forms
To address whether malignant T cells display a Treg phenotype in vivo, we performed immunohistochemical stainings of skin specimens from SS patients with an anti-FOXP3 Ab (236A/E7). In total, malignant T cells in 4 of 11 patients displayed a Treg phenotype as judged from FOXP3 reactivity in the skin. As exemplified in Figure 2a , the majority of malignant T cells displayed a strong nuclear staining in the FOXP3-positive patients. In contrast, cytoplasmic staining was only observed in a minority of malignant T cells and the stroma was overall negative (Figure 2a and data not shown). We also found that the leukemic T-cell lines, SeAx and Sez-4, established from two different patients with SS, displayed nuclear expression of FOXP3 ( Figure 2b ). To verify the specificity of the Ab, WB was performed on cell lysates from a FOXP3-positive cell line, a FOXP3-negative cell line and the SeAx cell line. As expected, a protein with a molecular weight of approximately 48 kDa equal to the molecular weight of wild-type (wt) FOXP3 was identified in the lysate from the FOXP3-positive cell line but not in the lysate from the FOXP3-negative cell line (Figure 3a) . Similarly, wt FOXP3 was detected in cell lysates from FOXP3-negative Jurkat cells transfected with wt FOXP3 but not Jurkat cells transfected with a vector control (Figure 3b) . Surprisingly, wt FOXP3 was not detectable in the SeAx cells (Figures 3a and b) . Thus, probing with an Ab (150D/E4) that selectively reacts with wt FOXP3 (exon 2) showed that the SeAx cells did not express detectable levels of wt FOXP3 (Figure 3b, lower panel) . However, two proteins of lower molecular weights were identified in the lysate from SeAx (but not in FOXP3-negative) cells by the FOXP3 Ab 236A/E7, which recognizes all known forms of FOXP3 (Figures 3a and b) . To address whether the two lowmolecular-weight proteins were identical to the two recently identified FOXP3 splice forms, FOXP3D2 and FOXP3D2D7 (Figure 1 ), we performed WB on cell lysates from SeAx cells and FOXP3-negative Jurkat cells transfected with a vector control, wt FOXP3 or one or both of the two low molecular splice forms of FOXP3. As shown in Figure 3c , the FOXP3 Ab (236A/E7) recognized wt FOXP3 and both the FOXP3 splice forms when expressed in Jurkat cells. The Ab also recognized the two lowmolecular-weight proteins in cell lysates from the SeAx cell line (Figure 3c ). The two low-molecular-weight proteins in the SeAx cells had molecular weights similar to that of the FOXP3D2 and FOXP3D2D7 splice forms expressed in Jurkat cells, but clearly lower than that of wt FOXP3 (Figure 3c ). Identical results were obtained with the Sez-4 cell line (data not shown). Further supporting the notion that the two proteins are low molecular splice forms of FOXP3, transfection of SeAx cells with FOXP3 siRNA induced a selective knock down of both bands, whereas the expression of Stat3 remained unaffected (Figure 3d ). Finally, both splice forms could be cloned from the SeAx and Sez-4 cell lines (data not shown) and, notably, no mutations were identified by sequence analyses (data not shown). As in the immunohistochemical analyses (Figure 2b) , the low molecular splice forms of FOXP3 were located within the nuclear fraction of SeAx and SeZ-4 cells (Figure 3e and data not shown). Collectively, these results provide evidence that the SeAx and Sez-4 cell lines selectively express the two low molecular splice forms, FOXP3D2 and FOXP3D2D7, of FOXP3. In general, the FOXP3D2D7 splice form was expressed at higher levels when compared with the FOXP3D2 splice form, but the expression of both splice forms varied to some degree depending on cell culture conditions (Figures 2b, 3 and 4 and data not shown). The expression of the FOXP3D2 splice form was very labile and seemed to be particularly sensitive to the culture conditions. To address whether primary malignant T cells in blood of SS patients also express the low molecular splice forms of FOXP3, cell lysates from peripheral blood of six SS patients were subjected to WB. It can be noted that two of these patients had also been included in the immunohistochemical analysis and found to be FOXP3-negative. As shown in Figure 3f , four of the patients expressed the two low molecular splice forms of FOXP3 in peripheral blood, whereas no expression of wt FOXP3 was detected using either the 236A/E7 or 150D/E4 Ab. Confirming our earlier findings, no expression of FOXP3 was observed in peripheral blood cells of the two patients found to be 
Expression of FOXP3 splice forms is driven by Jak3 and STAT5
Because aberrant activation of the Jak3/STAT signaling pathway is a hallmark of CTCL and seems to drive the malignant transformation, 10,34,36,37 we asked whether the expression of the FOXP3 splice forms was driven by Jak3. Accordingly, SeAx cells were treated with a Jak3 inhibitor (Jak3I), an inhibitor of the p38 MAP kinase (PD98059) or two Src kinase inhibitors (PP1, LckI) prior to the analysis of FOXP3 expression. As expected, the Jak3 inhibitor induced a dose-dependent inhibition of the constitutive STAT3 activity, whereas the other inhibitors did not (Figure 4a) . A selective inhibition of FOXP3 was also observed in cells treated with the Jak3 inhibitor as compared with cells treated with vehicle or the other inhibitors (Figure 4a ), indicating that Jak3 has an important function in the expression of the low molecular FOXP3 splice forms. To further substantiate this conclusion, SeAx cells were transfected with FOXP3, Jak3, STAT3 or STAT5a/b siRNAs prior to analyses of FOXP3 expression. Jak3 siRNA almost completely knocked down Jak3 expression, whereas other siRNAs had no effect on the expression of Jak3 (Figure 4b) . Similarly, FOXP3 siRNA blocked the expression of the FOXP3 splice forms (Figure 4b) . Importantly, the expression of the FOXP3 splice forms was also strongly inhibited by Jak3 siRNA when compared with the non-targeting siRNA control (Figure 4b) , supporting that Jak3, indeed, has an important function in the expression of the FOXP3 splice forms. IL-2-driven expression of FOXP3 has previously been shown to be mediated through STAT5. 38 In accordance, we found that downregulation of STAT5 expression severely inhibited the expression of the FOXP3 splice forms (Figure 4b ). However, STAT3 siRNA, which almost completely blocked STAT3 expression, had no inhibitory effect of FOXP3 expression (Figure 4b ). On the contrary, STAT3 inhibition repeatedly triggered an enhanced expression of FOXP3 (Figure 4b ), which is in keeping with recent observations that STAT3 can function as a repressor of FOXP3 expression. 38, 39 Malignant T cells spontaneously produce IL-10 and TGF-b and suppress non-malignant T cells Stat5) siRNAs. Subsequently, they were cultured for 48 h in cytokine-free media and total cell lysates analyzed by WB.
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T Krejsgaard et al immunodeficiency in CTCL. 40, 41 As shown in Figure 5a , the SeAx cells spontaneously produced IL-10 and TGF-b, whereas non-malignant T cells did not. Inhibition of Jak3 activity profoundly reduced the spontaneous production of IL-10, whereas an inhibitor of the epidermal growth factor receptor (Ag1478) had no effect (Figure 5a, left) . Similarly, downregulation of Jak3 expression by siRNA clearly reduced the spontaneous IL-10 production (Figure 5b ). The spontaneous TGF-b production was also reduced by the Jak3 inhibitor, although to a lesser extent (Figure 5a, right) . Because FOXP3 splice variants might have a role in the development and function of Tregs, we asked whether FOXP3 knockdown by siRNA inhibited the cytokine production of the SeAx cells. As shown in Figure 5b , FOXP3 siRNA had no detectable effect of the spontaneous IL-10 production. In contrast, STAT3 and, to some extent, STAT5 siRNA partially inhibited the spontaneous IL-10 production (Figure 5b) .
To address whether malignant T cells from SS patients function as Tregs, SeAx cells were co-cultured with nonmalignant T cells. Figures 6a and b show co-culture experiments between SeAx cells and non-malignant T cells in a semipermeable transwell system. As shown, the SeAx cells inhibited IL-2-driven proliferation of non-malignant T cells from a CTCL patient (Figure 6a ) and a mixed lymphocyte culture between healthy donors by approximately 40% (Figure 6b ). Knock down of FOXP3 splice forms by siRNA had no effect on the suppression (Figure 6a) , indicating that the FOXP3 splice forms are not involved in the execution of the Treg function of the malignant T cells. Direct co-culture between irradiated (to avoid proliferation) SeAx cells and non-malignant T cells did not trigger higher levels of suppression (data not shown), suggesting that the suppression is mediated by soluble factors rather than by direct cell contact. In support of this possibility, an IL-10RA blocking mAb and an IL-10 neutralizing mAb inhibited the Treg function of the SeAx cells (Figure 6b and data not show) . Because an anti-TGF-b Ab had little effect on the suppression (Figure 6b) , it seems that the suppression is mediated primarily by IL-10, which is in keeping with our observation that exogenous IL-10 inhibit an MLC by 40-50% (data not shown). The addition of exogenous IL-2 increased the proliferation of non-malignant T cell in both cultures with and without SeAx, but slightly inhibited the level of suppression from 54% in cultures without IL-2 to 37% in cultures with excess of IL-2 (data not shown). siRNAs and cultured for 48 h in cytokine-free media. Subsequently, the supernatants were harvested, and the IL-10 production was determined by ELISA. The IL-10 production is presented as percentage IL-10 production relative to SeAx cells transfected with NT siRNA. The data are from five (a) and four (b) independent experiments, respectively, performed with duplicate cultures. Error bars represent s.e.m.
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Malignant T cells display surface expression of CD25 but not of CTLA-4
In addition to FOXP3, a number of molecules have been linked to the Treg phenotype. In particular, not only high expression of the IL-2R a-chain (CD25) but also CTLA-4, GITR, and intracellular expression of Galectin-10 have been associated with Treg phenotype and function. 42, 43 As shown previously 26, 37 and confirmed here, SeAx cells express high levels of CD25 (Figure 7c ). CTLA-4, which has a critical function in cell-mediated suppression, 44 was detected at the mRNA level (Figure 7a ) and by intracellular staining (Figure 7d ), but no significant surface expression could be detected even after treatment with phorbol ester and ionomycin (data not shown). Similarly, GITR was detected at the mRNA level (Figure 7a ) but barely detectable at the protein level (data not shown). In contrast, Galectin-10 mRNA was not detected in either the SeAx or Sez-4 cell line (Figure 7b ).
FOXP3 wt and splice forms have different effects on NF-kB activity in luciferase assays
The NF-kB signal pathway has been shown to be constitutively active and essential for the protection from apoptosis in peripheral blood tumor cells and T-cell lines from patients with SS. 45 In accordance, we found that NF-kB exhibited constitutive nuclear localization in the SeAx cell line (Figure 3e ) and that an inhibitor of NF-kB transcriptional activation 46 (NF-kBI) induced dose-dependent growth arrest in the SeAx cells (Figure 8a ). Given previous findings that wt FOXP3 inhibits NF-kB activity, 24 it was interesting to address whether the low molecular splice forms of FOXP3 also inhibit NF-kB transcriptional activity. Therefore, Jurkat T cells were transfected with a vector control, FOXP3 wt, FOXP3D2 or FOXP3D2D7 prior to the measurement of flagellin-induced NF-kB activity using a luciferase reporter construct. As shown in Figure 8b , flagellin triggered a profound NF-kB-mediated transcriptional activity as judged from the increase in luciferase activity. FOXP3 wt inhibited the flagellin induced increase in NF-kB activity. In contrast, the FOXP3 splice forms had little or no inhibitory effect on the flagellininduced transcriptional activity of NF-kB (Figure 8b , upper panel) despite comparable levels of mRNA expression as wt FOXP3 (Figure 8b, lower panel) . Similar effects of FOXP3 wt and splice forms were seen on IL-1b-induced NF-kB reporter activity (data not shown).
Discussion
In this study, we provide the first evidence that malignant T cells from SS selectively express low molecular splice forms of FOXP3 in vivo. Furthermore, we show that the malignant T cells can function as Tregs in vitro. Thus, the malignant T cells Our findings that some malignant T cells from SS patients express FOXP3 splice forms are in apparent contrast to a recent report by Klemke et al. 17 However, Klemke et al. did not specifically investigate the expression of the splice forms. Moreover, as we only find FOXP3 expression in a subpopulation of patients, it is likely that variations between the cohorts of patients might explain our different observations. From our study, it was not possible to assign FOXP3 expression to certain subgroups of patients, and future investigations are needed to elucidate the frequency of FOXP3-positive patients and whether the expression of FOXP3 splice forms is associated with clinical subgroups of SS.
Although the SeAx cell line was reported to be FOXP3 negative, 17 we have been able to clone the FOXP3 splice forms from this cell line and find it to be FOXP3 positive in immunohistochemistry (Figure 1b) , WB ( Figure 3 ) and RT-PCR (Figure 7 ). This discrepancy could be explained by differences in SeAx sublines, in assay sensitivity, and to some degree, by variations in cell culture conditions between the two studies, as we find that the level of FOXP3 expression in SeAx cells is influenced by the culture conditions.
Our findings that malignant T cells selectively expressing FOXP3 splice forms function as Tregs suggest that the expression of splice forms (like wt) in combination with CD25 is a maker of a Treg phenotype. However, siRNA-mediated downregulation of the FOXP3 splice forms did not inhibit cytokine production or Treg function. Thus, our data suggest that the FOXP3 splice forms might be involved in the differentiation of malignant Treg cells but not in the execution of the suppressive effect. The observations that the expression of the FOXP3 splice forms relied on Jak3/STAT5 but not on STAT3, whereas cytokine production was partly dependent on STAT3, support this conclusion.
One of the main questions, which arise from this study, is why the malignant T cells selectively express the low molecular splice forms of FOXP3 and not wt FOXP3. In some experimental models, wt FOXP3 has been shown to have an anti-proliferative effect. 22, 47 However, downregulation of the FOXP3 splice forms had no effect on the spontaneous proliferation of the SeAx cells (Supplementary Figure 1) , suggesting that the splice forms have no repressive effect on malignant proliferation. In support of this conclusion, Allan et al. 21 showed that FOXP3D2 had little antiproliferative effect when expressed in transduced T cells relative to wt FOXP3. It has previously been reported that wt FOXP3 inhibits the transcriptional activity of NF-kB. 24 However, NF-kB is constitutively activated in malignant T cells from SS patients where it has an essential function by inhibiting apoptosis. 45 Therefore, it was crucial whether the low molecular splice forms of FOXP3 also inhibited NF-kB transcriptional activity. Expectedly, wt FOXP3 strongly inhibited NF-kB transcriptional activity in Jurkat cells, whereas the FOXP3 splice forms did not. This finding is in agreement with previous rapports identifying exon 2 as a central part of the transcriptional repressor domain in FOXP3 [23] [24] [25] ( Figure 1 ). Thus, our findings suggest that selective expression of the FOXP3 splice forms may protect the malignant T cells from an anti-proliferative effect of wt FOXP3 while retaining the anti-apoptotic effect of NF-kB. This is the first investigation of FOXP3 splice forms in a human disease. Given present and previous findings showing that wt FOXP3 and splice forms appear to have overlapping but partly different functions, our observation of a selective expression of FOXP3 splice forms in SS might have implications for other studies of FOXP3 expression in tissue samples and blood. 21, 22, 25 Thus, most immunohistochemical and flow cytometric studies of FOXP3 expression do not discriminate between wt FOXP3 and the low-molecular-weight splice forms. Much important information on the function and clinical importance of FOXP3 versus splice forms awaits a better characterization of most anti-FOXP3 Abs used in human studies.
In conclusion, we provide the first evidence that malignant T cells from SS patients selectively express FOXP3 splice forms and that the splice forms differ functionally from wt FOXP3 in terms of the regulation of NF-kB activity. As malignant expression of FOXP3 splice forms and Treg function is driven by Jak3, our study adds to the understanding of the role of the Jak3/STAT signaling pathway in malignant transformation, immune evasion and immunodeficiency in cancer.
